

# APSA-ASCEPT JOINT SCIENTIFIC MEETING 5-8 DECEMBER 2017 BRISBANE CONVENTION & EXHIBITION CENTRE

# Program

Optimising medicines for optimal patient outcomes



www.apsa-ascept2017.com #APSAASCEPT

Download the meeting app Event code: apsa-ascept



### **Tuesday 5 December 2017**

09:00 - 18:00	Registration desk open					
	Boulevard foyer, Brisbane Convention & Exhibition Centre					
10:00 start	ASCEPT Board meeting (10:00 – 12:30)	Council of Pharmacy Schools meeting (10:00 – 12:30)	Pharmacogenomics Workshop (10:00 – 12:00)	Workshop: Careers and Early Stage Biomedical Translation (10:00 – 16:45)		
	Room: Arbour Boardroom	Room: Meeting room B3	Room: Meeting room B2	Room: Meeting room B1		
			Chair: Prof Andrew Somogyi	Supported by		
			Thiopurine pharmacogenetics: From classic simplicity to modern complexity Dr John Duley, The University of Queensland	Accelerating Australia Supported by MTPConnect Hettes and Parties formed from		
			Research and education programs facilitating evidence- based clinical implementation of pharmacogenomics and precision medicine in Australia Assoc Prof Liz Milward, The University of Newcastle	10:00 – 12:30 Overview of the life sciences industry from an Australian Perspective Dr Phil Kearney, Merck Sharp & Dohme Australia and Prof Daniel Hoyer, The University of Melbourne		
			Student/ECR short presentations	Transformational stage of the industry resulting in		
			Pharmacogenomics SIG AGM	opportunities for biomedical		
		Clinical Pharmacology	Education Forum	entrepreneurs		
		Workshop (13:30 – 16:45) Room: Meeting room B3	(12:30 – 16:45) Room: Meeting room B2	What is a biomedical		
		Clinical Pharmacology SIG	ASCEPT Education Forum AGM	entrepreneur? Prof Maree Smith, The		
		AGM	Engaging students in the	University of Queensland and		
		Clin Pharm Noir — A case- based, interactive workshop on forensic toxicology Can the living help the deceased? Assoc Prof Darren Roberts, NSW Poisons Information Centre, Sydney Children's Hospital Network, Westmead	digital world Dr Kirsten Staff and Dr Sheridan Gentili, University of South Australia Preparing educators to deal with the challenges of an ever- changing higher education environment Assoc Prof Lesley Lluka, The	Prof Darren Kelly, The Universit of Melbourne		
				12:30 – 13:15 Lunch		
				<ul> <li>13:15 – 16:45</li> <li>What is happening in our biomedical translation ecosystem?</li> <li>Assoc Prof Kevin Pfleger, Harry Perkins Institute of Medical</li> </ul>		
		The final consult Prof Nick Buckley, The	University of Queensland and Assoc Prof Shane Bullock, Monash University	Research and University of Western Australia Facilitated and interactive		
		University of Sydney <b>Poisoning through the ages</b> Prof Ian Whyte, Calvary Mater Newcastle		workshop to identify the main hurdles for biomedical translation in Australia from the perspective of participants		
17:00 - 18:00	Conference opening and Japa	anese Pharmacological Society key	note address			
	Room: Boulevard Auditorium					
	Chair: Prof Dom Geraghty					
	and pharmacogenomics on P	concept" in new drug discovery and K/PD/TD of drugs - 100 na Laboratory, RIKEN Innovation Cer		effect of drug-drug interaction		
18:00 - 19:30	Welcome reception					
	Boulevard foyer, Brisbane Cor	vention & Exhibition Centre				

### **Social media policy**

Meeting attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual's specific scientific result on any forum including social media.

We respectfully ask that if you attend a presentation where a presenter has communicated that they do not wish to have their presentation commented on in the social media environment that you adhere to this request.

If you are presenting preliminary or unpublished data, and do not wish the results to be broadcast, please use the following logo with your presentation asking the audience to refrain from posting your material. It should appear on the title slide or poster, and if you like, any slides you do not want posted or commented on, so that your audience recognises your request.



## Wednesday 6 December 2017

07:30 - 18:00	Registration desk open					
	Boulevard foyer, Brisbane Convention & Exhibition Centre					
08:30 - 09:30	APSA lecture					
	Room: Boulevard Auditorium					
	Chair: Dr Joe Nicolazzo					
	Reflections and connections on	a pharmacokinetic journey – 10				
	Prof Kevin Batty, School of Pharm		-			
09:30 - 10:20			Supported by	DBCRUE	APSA Council meeting	
05.50 10.20	Poster presentations: Cardiovas	cular Clinical Pharmacology	Supported by	TO AND		
	Drug Discovery, Toxicology, Phar		Ling L		Room: Meeting room B1	
	Drug Discovery, toxicology, that					
10:25 - 12:30	<b>Symposium 1:</b> Cannabinoids	Symposium 2: Novel aspects	Symposium 3: Mice, n		Symposium 4: Optimising	
	for patients: Getting the	of drug metabolising enzymes - structure, function and	and post-marketing su		teaching to enhance student outcomes	
	pharmacology right first time	regulation	to inform medication e and safety	епісасу	outcomes	
	Supported by		and salety			
	🔨 Queensland					
	🕵 🕅 Government					
	Room: Boulevard Auditorium	<b>Room:</b> Meeting room B3	Room: Meeting room	22	<b>Room:</b> Meeting room B1	
	Chair: Prof Jennifer Martin	Chairs: Prof Ross McKinnon and	Chairs: Dr Danijela Gnj		Chairs: Dr Lynette Fernandes	
		Prof Peter Mackenzie	Assoc Prof Simon Bell		and Dr Greg Maynard	
10:25 - 10:50	Understanding cannabinoid	Cytochrome P450 structure	Preclinical models to		Introducing a large-scale	
	clinical pharmacology in order	- function: Insights from	understand the risks o	of single	research project for	
	to drive clinical studies – 102	molecular dynamics	and multiple concurre		undergraduate students – 117	
	Dr Catherine Lucas, University	simulations – 107	medicines in old age -		Assoc Prof Susan Rowland, The	
	of Newcastle	Prof John Miners and Dr	Dr John Mach, Kolling		University of Queensland	
		Pramod Nair, Flinders University		he		
40.50 44.45			University of Sydney		<b>.</b>	
10:50 - 11:15	Cannabinoids for patients:	CYP2J2 over-expression in breast cancer cells drives	Application of pharma		Peer assessment to	
	Comparative efficacy and toxicity in a paediatric setting	tumourigenesis and anti-	modelling for studying effects – 113	garug	develop critical analysis and self-reflection in large	
	- 103	cancer drug resistance – 108	Prof Carl Kirkpatrick, N	Ionash	undergraduate cohorts – 118	
	Prof Noel Cranswick,	Prof Michael Murray, The	University	nonasn	Dr Rosa McCarty, The Universit	
	Melbourne University	University of Sydney	Oniversity		of Melbourne	
11:15 – 11:40	High quality human	Regulation and function of	Novel approaches in		Development of	
	cannabinoid analytics to drive	UGTs in cancer – 109	pharmacoepidemiolo	gical	interprofessional	
	clinical studies – 104	Dr Robyn Meech, Flinders	studies to communica		communication skills for	
	Dr Peter Galettis, University of	University	benefits and risk of m	edicines	interprofessional collaboration	
	Newcastle		- 114		- 119	
			Dr Danijela Gnjidic, Th	e	Dr Karen Luetsch, The	
			University of Sydney		University of Queensland	
11:40 - 12:05	Pharmacokinetic analysis	Arylamine	Pharmacoepidemiolo		Student perspectives on peer	
	of vaporized cannabinoids	N-acetyltransferase-1: Drug	studies to inform med		assessment, feedback and	
	through inhalation – 105	metabolism and more – 110	safety in older adults		team work – 120	
	Dr Zheng Liu, University of	Dr Neville Butcher, The	chronic diseases and o	aementia	Mr Jayden Kelly and Mr	
	Newcastle	University of Queensland	- 115 Assoc Brof Simon Boll	Monach	Mohammdali Taher, Monash	
			Assoc Prof Simon Bell, University	WONASH	University	
12:05 - 12:30	Pharmaceutical aspects of	Sulfotransferase: Structure,	Changing guideline		Panel discussion	
12.03 - 12.30	cannabis – 106	function and protein-protein	recommendations on	the		
	Assoc Prof Jennifer Schneider,	interactions – 111	pharmacological man			
	University of Newcastle	Prof Rodney Minchin, The	of back pain – 116	J		
		University of Queensland	Assoc Prof Christine Li	n, The		
			George Institute for Gl			
			Health			
12:30 - 13:25						
		cular, Clinical Pharmacology, Drug				
	Drug Disposition and Response	SIG Pharmacoepidemiol			1 (12:45 – 14:00)	
	meeting			(please tak	e lunch into room with you)	
	Room: Meeting room B3	Room: Meeting room			eting room B1	

13:30 - 15:30	Oral presentations 1: Drug Discovery/ Pharmaceutical Science Supported by HARMACOLOGY	Oral presentations 2: Cardiovascular	ASCEPT Gillian Shenfield Early Educator Award	
	Room: Boulevard Auditorium	Room: Meeting room B3	Room: Meeting room B2	
	Chair: Dr Lauren May	Chair: Dr Tracey Gaspari	Chair: Dr Lynette Fernandes	
13:30 – 13:45	Quantification of metformin in human serum by hydrophilic interaction liquid chromatography - mass spectrometry – 121 Dr Ahmed Abdalla, University of South Australia	Cardiomyocyte ErbB4 receptors are essential for cardiac hypertrophy and growth of neonatal mice, and contribute to maintenance of cardiac function in adult hearts – 129 Dr Melissa Reichelt, The University of Queensland	Developing a new unit in a new curriculum – 137 Dr Betty Exintaris, Monash University	
13:45 - 14:00	ORAI1 calcium channels in cell death during mammary gland involution – 122 Dr Felicity Davis, The University of Queensland	Comparing the anti- fibrotic effects of emerging treatments: Serelaxin and the IRAP inhibitor, HFI-419 to a clinically-used angiotensin receptor blocker and ACE inhibitor in a high salt-induced		
		mouse model of kidney disease – 130 Mr Matthew Shen, Monash University	Oral presentations 3: Pharmacoepidemiology	Oral presentations 4: Cancer theme
			Room: Meeting room B2	Room: Meeting room B1
			Chair: Prof Andrew McLachlan	Chair: Prof Alan Boddy
14:00 - 14:15	Pre-clinical pharmacokinetic development of the hypoxia- activated cytotoxin SN36506 – 123 Dr Matthew Bull, The University of Auckland, New Zealand	Role of TRPC3 in endothelium- dependent vasodilation of rat mesenteric arteries – 131 Dr Sarah Wright, University of New South Wales	What are the predictors of persistent prescription opioid analgesic use for non-cancer pain in Australia? – 138 Mrs Samanta Lalic, Monash University	Population pharmacokinetics of carboplatin, etoposide and melphalan (CEM) in children with high-risk neuroblastoma – 144 Dr Janna Duong, The University of Sydney
14:15 - 14:30	A new high-throughput approach for investigating GPCR internalisation in real- time – 124 Dr Simon Foster, University of Copenhagen, Denmark	Targeting IRAP: A novel treatment to stabilise existing abdominal aortic aneurysms – 132 Mr Kaki Fan, Monash University	Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: An Australian population-based cohort study – 139 Ms Huah Shin Ng, University of South Australia	The novel fatty acid epoxide analogue CTU targets the mitochondrion and depletes cardiolipin to promote killing of MDA-MB-231 breast cancer cells – 145 Mr Hassan Choucair, The University of Sydney
14:30 - 14:45	CSKSSDYQC peptide conjugated N-trimethyl chitosan enhance the oral bioavailability of gemcitabine by targeting goblet cells – 125 Assoc Prof Jingyuan Wen, University of Auckland, New Zealand	Inhibition of the transient receptor potential melastatin 7 (TRPM7) channel-kinase improves cardiac function in an <i>ex vivo</i> model of ischaemia/ reperfusion injury – 133 Dr Tamara Paravicini, RMIT University	Antithrombotic prescribing for patients with a history of atrial fibrillation: An analysis using MedicineInsight data – 140 Dr Daniel Taylor, NPS MedicineWise	The potential of MK2 inhibitors in glioblastoma therapy – 146 Assoc Prof Lenka Munoz, The University of Sydney
14:45 - 15:00	Nicotine-loaded chitosan nanoparticulate dry powder inhaler formulation for its activity – 126 Dr Nazrul Islam, Queensland University of Technology	Functional regulation of bitter taste receptors by beta2- adrenergic and M2 muscarinic acetylcholine receptors – 134 Mr Jilai Zhao, The University of Queensland	Questions from Australian public and health professionals on medication use in breastfeeding: Comparative call analysis of two national medicines call centres – 141 Dr Treasure McGuire, The University of Queensland	Induction of apoptosis in triple negative breast cancer cells by selenium derivatives – 147 Ms Jackmil Puthoor Jogy, University of Otago, New Zealand

# Research opportunities at the School of Health and Biomedical Sciences

# RMIT UNIVERSITY

### For further information:

https://www.rmit.edu.au/about/our-education/academic-schools/health-and-biomedical-sciences/research


15:00 - 15:15	Monitoring NanoBRET ligand binding to endogenous adenosine A <sub>28</sub> receptors – 127 Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research	Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes – 135 Dr Miles De Blasio, Baker Heart & Diabetes institute	Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive impairment: A systematic review – 142 Mr Mitchell Redston, The University of Sydney	The effect of curcumin on in vitro metabolism and predicted <i>in vivo</i> exposure of imatinib – 148 Mr Jeffry Adiwidjaja, The University of Sydney
15:15 – 15:30	Dual action calcium sensing receptor modulator, calhex231, unmasks novel mode-switching mechanism - 128 Dr Karen Gregory, Monash University	Systemic and cardiac- selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy – 136 Mr Andrew Willis, Monash University	Health professionals' and researchers' opinions on conducting clinical deprescribing trials – 143 Mr Alexander Clough, The University of Sydney	Triterpenoid micellar nanoparticles for the treatment of glioblastoma: Potential inhibition of the PI3K/Akt signaling – 149 Dr Rebecca Roubin, The University of Sydney
15:30 - 15:55	Afternoon tea with exhibitors			Cardiovascular SIG meeting
16:00 - 18:00	Oral presentations 5: Pharmacy Practice	Oral presentations 6: Drug Disposition and Response/Pharmaceutical Science Supported by	Oral presentations 7: Urogenital and Gastrointestinal Supported by	Room: Meeting room B3 Oral presentations 8: Neuro- and Behavioural Pharmacology
		•TECAN•	Castellas Leading Light for Life	
	Room: Boulevard Auditorium	Room: Meeting room B3	Room: Meeting room B2	Room: Meeting room B1
	Chair: Dr Petra Czarniak	Chair: Dr Andrew Crowe	Chair: Dr Michael Winder	<b>Chair:</b> Assoc Prof Marie Odile- Parat
16:00 - 16:15	Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross- sectional study – 150 Mr Mulugeta Angamo, University of Tasmania	Troches or orally dissolving tablets for delivery of pilocarpine in treatment of xerostomia (dry mouth)? – 158 Mrs Rose Estafanos, The University of Queensland	Pulsed magnetic stimulation for persistent post- prostatectomy stress urinary incontinence: A pilot study - 166 Dr Renly Lim, University of South Australia	Morphine dosing affects development of antinociceptive tolerance and motor behavior – 174 Mr Alok Kumar Paul, University of Tasmania
16:15 – 16:30	Investigating the impact of Universal Healthcare Coverage on the practice of Indonesian Community Pharmacy: A qualitative study – 151 Mr Andi Hermansyah, The University of Sydney	Lipophilic salts of small molecule kinase inhibitors for increased oral bioavailability using lipid formulations – 159 Dr Leigh Ford, Monash University	Pharmacological effects of a jungle ginger on rat prostatic smooth muscle – 167 Ms Nguok Ngie Eunice Su, Monash University	Increased osmotic pressure promotes glioblastoma invasiveness – 175 Miss Wenjun Pu, The University of Queensland
16:30 - 16:45	Home Medicines Reviews - exploring accredited pharmacists' work processes - 152 Ms Marea Patounas, Queensland University of Technology	Triglyceride-mimetic prodrugs of testosterone significantly enhance lymphatic transport and oral bioavailability – 160 Dr Tim Quach, Monash University	Post-hospital changes in medication regimen complexity and potentially inappropriate medication use in older adults with chronic kidney disease – 168 Mr Wubshet Tesfaye, University of Tasmania	Discovering methyllycaconitine analogues specific for $\alpha_4 \beta_2$ over $\alpha$ 7 nAChR subtypes – 176 Prof Mary Chebib, The University of Sydney
16:45 – 17:00	Adoption of the Ohio Emergency Department opioid prescribing guidelines – 153 Dr Jonathan Penm, The University of Sydney	Characterising and predicting the <i>in vivo</i> kinetics of therapeutic mesenchymal stem cells and their secretome – 161 Dr Haolu Wang, The University of Queensland	Effect of Rho-kinase inhibitors on contractility of porcine corpus cavernosum – 169 Miss Amelia Jack, Bond University	Inhibition of $\alpha_{s}\beta_{1}$ with the clinically validated small peptide ATN-161 is neuroprotective and functionally restorative in experimental stroke – 177 Ms Danielle Edwards, University of Kentucky, USA

### Discover a career in health

THE UNIVERSITY OF SYDNEY With the widest range of health courses of any Australian university, we equip you for a career in one of the fastest growing sectors in the world.

sydney.edu.au/courses/medicine-and-health

17:00 – 17:15	Pharmacy in the community: The potential of role extension – 154 Dr Caroline Morris, University of Otago, New Zealand	Permeation of quercetin through the human epidermis – 162 Dr Azadeh Alinaghi, University of South Australia	The effects of aging on polarization in collagen sandwich-cultured hepatocytes – 170 Miss Sun Woo Kang, Anzac Research Institute	Morphine regulates cellular migration and invasion by modifying the circulating proteolytic profile in mice – 178 Miss Nan Xie, The University of Queensland
17:15 – 17:30	Just rubbish? Examining the concerns and attitudes of pharmacists to pharmaceuticals entering the environment – 155 Mrs Judith Singleton, Queensland University of Technology	Evaluation of optimised piperacillin plus tobramycin combination dosage regimens against <i>Pseudomonas</i> <i>aeruginosa</i> (Pa) for patients with altered pharmacokinetics <i>via</i> the hollow fibre infection model and mechanism-based modelling – 163 Mr Rajbharan Yadav, Monash University	Human 5-HT <sub>3</sub> AC receptors are subtly different to 5-HT <sub>3</sub> A receptors – 171 Prof Helen Irving, La Trobe University	Stress induced analgesia is reduced in neuropathic pain states – 179 Mr Nicholas Atwal, The University of Sydney
17:30 – 17:45	Adherence to lipid lowering medications for secondary prevention of stroke – 156 Mrs Judith Coombes, The University of Queensland; Princess Alexandra Hospital	CMF-019, the first G protein biased small molecule apelin agonist, is a vasodilator and positive inotrope <i>in vivo</i> – 164 Mr Cai Read, University of Cambridge, UK	Characterization of Na, channels in colon-innervating dorsal root ganglion neurons in mice – 172 Ms Andelain Erickson, The University of Adelaide	Phytocannabinoid actions in an animal model of neuropathic pain – 180 Miss Jessica Falon, The University of Sydney
17:45 – 18:00		Polymer precipitation inhibitors can maintain drug supersaturation and increase in vivo absorption from lipid- based formulations – 165 Ms Estelle Suys, Monash University	Histamine receptor (Hrh) subtypes mediate bladder afferent sensitivity in mice – 173 Ms Ashlee Caldwell, The University of Adelaide	Nesfatin-1 suppresses feeding and induces emesis in Suncus murinus (House Musk Shrew) – 181 Dr Sze Wa Chan, Caritas Institute of Higher Education, Hong Kong
19:30	AAPS student dinner	1		
	The Plough Inn, 29 Stanley St, So	uth Brisbane		



# **APSA Annual Conference**

2–5 December 2018 University of South Australia, Adelaide

www.apsa-online.org

MONASH

# MONASH PHARMACY AND PHARMACEUTICAL SCIENCES

Proud sponsor of APSA-ASCEPT 2017

### monash.edu/pharm

17P-1214. Nov 2017. SMC, Monash University. CRICOS provider: Monash University 00008C, Monash College Pty Ltd 01857J

### Thursday 7 December 2017

08:00 - 17:00	Registration desk open						
	Boulevard foyer, Brisbane Convention & Exhibition Centre						
08:30 - 09:30	British Pharmacological Society keynote address						
	Room: Boulevard Auditorium						
	Chair: Prof Dom Geraghty						
	Innovations in clinical pharmaco	plogy education – 200					
		versity Medicine Malaysia, Malays	ia				
09:30 - 10:25	Morning tea with exhibitors						
	Poster presentations: Drug Disposition and Response, Inflammation/Respiratory, Neuro- and Behavioural Pharmacology,						
			ointestinal, Pharmacy Practice, Ed				
10:30 - 12:30	Symposium 5: Why is	Symposium 6: New strategies	Symposium 7: Novel targets for	Symposium 8: Improving			
	polypharmacy increasing in	to treat chronic inflammatory	the treatment of pain	biomolecule behaviour			
	aged care facilities and what	diseases					
	can we do about it?	Supported by	Supported by				
		RMIT	THE UNIVERSITY OF QUEENSLAND				
		UNIVERSITY	Institute for Molecular Bioscience				
	<b>Room:</b> Boulevard Auditorium	Room: Meeting room B3	Room: Meeting room B2	Room: Meeting room B1			
	Chair: Ms Natali Jokanovic	Chairs: Assoc Prof Ross Vlahos	Chairs: Prof Richard Lewis and	Chair: Prof Rodney Minchin			
		and Prof Emilio Badoer	Assoc Prof Irina Vetter				
10:30 - 11:00	Increasing polypharmacy in	Adipokines, cardiovascular	Decoding spinal cord circuits	CESTEM-1 clinical trials: Using			
	aged care facilities: Trends,	function and brain	to find novel targets for	dynamin inhibitors to reverse			
	problems and solutions – 201	inflammation – 205	chronic pain – 209	resistance to monoclonal			
	Ms Natali Jokanovic, Monash	Prof Emilio Badoer, RMIT	Dr Wendy Imlach, Monash	antibody therapy – 213			
	University	University	University	Dr Fiona Simpson, The			
				University of Queensland			
11:00 - 11:30	How is Canada addressing	Mineralocorticoid and	Nav1.7 as a target for pain	i-bodies against the			
	the increasing burden of polypharmacy? – 202	estrogen receptors: Novel therapeutic targets in	treatment: Therapeutic challenges and opportunities	chemokine receptor CXCR4 with novel pharmacology –			
	Dr Justin Turner, University of	cardiovascular disease and	-210	214			
	Montreal, Canada	stroke? – 206	Dr Sulayman Dib-Hajj, Yale	Dr Michael Foley, La Trobe			
		Prof Chris Sobey, Latrobe	University, USA	University			
		University					
11:30 - 12:00	Integrating prescribing and	The paradox of Z-drugs in	GPCRs and ion channels:	Antibody-polymer-drug			
	dispensing data across primary	motor recovery after stroke	The cause of and solution to	conjugates for biomedical			
	care, hospitals and aged care:	- 207	chronic visceral pain? – 211	applications – 215			
	The MedView Project – 203	Prof Mary Collins, The	Assoc Prof Stuart Brierley,	Dr Charlotte Williams,			
	Mr David Freemantle, Fred IT Group	University of Sydney	Flinders University; SAHMRI	Commonwealth Scientific and Industrial Research			
	Gloup			Organisation (CSIRO)			
12:00 - 12:30	Application of a structured	Targeting oxidant-dependent	Mechanosensors and pain	Downsizing disulfide-rich			
12.00	approach to simplify	pathways to treat cognitive	- 212	bioactive peptides – 216			
	medication regimens in	dysfunction in chronic	Dr Kate Poole, University of	Dr Richard Clark, The Universit			
	residential aged care – 204	obstructive pulmonary disease	New South Wales	of Queensland			
	Dr Janet Sluggett, Monash	- 208					
	University	Assoc Prof Ross Vlahos, RMIT					
12.20 42.25		University		Taviaslam SIC marting			
12:30 – 13:25	Lunch with exhibitors		Supported by	Toxicology SIG meeting			
	Poster presentations: Drug Dispo		CP3 Inc. Council of Pharmacy Schools: Australia & New Zealand	Room: Meeting room B1			
	initiation in the spiratory, we are and benavioural marinacology,						
	Pharmacoepidemiology, Pharmacogenomics, Urogenital and Gastrointestinal, Pharmacy Practice, Education						

### Queensland Health Medicinal Cannabis in Queensland

The key changes are:

- The Public Health (Medicinal Cannabis) Act 2016 and subordinate Regulations
- Clinical Guidance: for the use of medicinal cannabis products in Queensland: March 2017
- Standard for security of medicinal cannabis stock: January 2017

Visit www.health.qld.gov.au/public-health/topics/medicinal-cannabis



13:30 - 15:30	Oral presentations 9: Garth McQueen student oral prize	Oral presentations 10: Clinical Pharmacology	Oral presentations 11: Pharmacy Practice	Oral presentations 12: Respiratory/Toxicology
		Supported by Therapeutic Guidelines		
	Room: Boulevard Auditorium Chair: Dr Tina Hinton	Room: Meeting room B3 Chair: Assoc Prof Matt Doogue	Room: Meeting room B2 Chair: Dr Carl Schneider	Room: Meeting room B1 Chairs: Emeritus Prof Roy Goldie and Dr Ian Musgrave
13:30 - 13:45	Gene delivery targeting cardiac O-GlcNAc modification limits diabetic cardiomyopathy – 217 Mr Darnel Prakoso, The Baker Heart and Diabetes, The University of Melbourne	Microdosed cocktail of apixaban, edoxaban and rivaroxaban can predict drug interaction with therapeutic doses – 225 Prof Gerd Mikus, University Hospital Heidelberg, Germany	Identifying clinical pharmacist patient prioritisation criteria – 233 Mrs Nazanin Falconer, The University of Queensland	Vale Domenico (Dom) Spina Emeritus Prof Roy Goldie, Flinders University
13:45 - 14:00	The safety of metformin in haemodiafiltration – 218 Miss Felicity Smith, University of New South Wales; St Vincent's Hospital	The influence of ABCG2 genotype on allopurinol dose predictions – 226 Dr Daniel Wright, University of Otago, New Zealand	Evaluation of a quantitative approach for analysis of semi-structured pharmacy consumer interviews – 234 Mr Ardalan Mirzaei, The University of Sydney	IRAK3 modulates NFκB through its guanylate cyclase activity – 241 Ms Lubna Freihat, Monash University
14:00 - 14:15	Neuronal calcium sensor-1 (NCS-1) in the regulation of calcium homeostasis and cell death in MDA-MB-231 basal breast cancer cells – 219 Miss Alice Bong, The University of Queensland	Late onset rise of 6-MMP metabolites in inflammatory bowel disease patients on azathioprine or mercaptopurine – 227 Prof Murray Barclay, Christchurch Hospital, New Zealand	Response of community pharmacy staff to a request for an antibiotic product without a valid prescription: A simulated client study in Sri Lanka – 235 Mr Shukry Zawahir, The University of Sydney	Intranasal delivery of the TLR7 agonist, imiquimod, protects against influenza A virus- induced morbidity in mice – 242 Mr Jonathan Erlich, RMIT University
14:15 - 14:30	The relationship between busulphan AUC and the incidence of sinusoidal obstruction syndrome in haematopoietic stem cell transplants – 220 Mr Parth Upadhyay, The University of Sydney	Minimising the functional burden of medications in older inpatients: Implementation of the Drug Burden Index – 228 Ms Rayan Nahas, Royal North Shore Hospital	What Is Polypharmacy Exactly (WIPE) – 236 Ms Nashwa Masnoon, University of South Australia	A novel endosomal NOX2 oxidase inhibitor protects against high pathogenicity influenza A virus-induced disease – 243 Ms Eunice To, RMIT University
14:30 - 14:45		A stimulation study to assess the possible contribution of measurement error in quetiapine depression trials – 229 Ms Jia Ning Careen Tan, The University of Queensland	Psychotropic medicines use in Residents And Culture: Influencing Clinical Excellence (PRACTICE) tool: A development and content validation study – 237 Miss Mouna Sawan, The University of Sydney	Localisation of polymyxin in human alveolar epithelial cells – 244 Mr Maizbha Uddin Ahmed, Monash University
14:45 - 15:00	The Medication Regimen Simplification Guide for Residential Aged CarE (MRS GRACE): A novel tool to optimise medication regimens for residents of aged care facilities. – 222 Ms Esa Chen, Monash University	A multicentre open- label pharmacokinetic- pharmacodynamic study of febuxostat in patients with chronic gout – 230 Mr Bishoy Kamel, University of New South Wales; St Vincent's Hospital	"Good prescribing is a bit like good driving; everybody thinks they're a good driver." An exploratory study on the barriers and facilitators to using quality prescribing indicators (QPIs) in general practice – 238 Dr Li Shean Toh, University of Tasmania	Pharmacological characterisation of small molecule C5aR1 inhibitors in primary human macrophages – 245 Ms Xaria Li, The University of Queensland

Biomedical entrepreneurship courses and early stage commercialisation support: Connecting innovative ideas to the right expertise





Accelerating

@acceleratingaus

5

Connect with Us

www.acceleratingaustralia.com

15:00 - 15:15	Behavioural, pharmacologic and histologic characterisation of a rat model of mechanical low back pain – 223 Mr Thomas Park, The University of Queensland	The safety and pharmacokinetics of metformin in heart failure – 231 Mrs Gina Chowdhury, University of New South Wales; St Vincent's Hospital	Contextualised medication information is critical to treatment uptake and adherence among people living with HIV – 239 Dr Amary Mey, Griffith University	Getting under the skin – why receptor fluid choice is crucial in <i>in vitro</i> skin permeation tests – 246 Dr Ana Macedo, University of South Australia					
15:15 - 15:30	Understanding the physiological role of endogenous allosteric modulators in the muscarinic acetylcholine receptors – 224 Ms Ee Von Moo, Monash University	Vignettes from hospital-level electronic prescribing data – 232 Dr Paul Chin, Canterbury District Health Board, New Zealand	A study on usual Residential Medication Management Review (RMMR) practice – 240 Mrs Leila Shafiee Hanjani, The University of Queensland	Can an educational intervention lead to a sustained reduction in gastric lavage for poisoning admissions? – 247 Dr Jacques Raubenheimer, The University of Sydney					
15:30 - 15:55	Afternoon tea with exhibitors			Respiratory & Inflammation SIG meeting					
				Room: Meeting room B1					
16:00 - 17:00	ASCEPT Rand Medal Lecture								
	Room: Boulevard Auditorium								
	Chair: Prof Dom Geraghty								
		al patient outcomes? Perhaps we edical School, The University of Sy	<b>e need more comparative ineffe</b> dney	ctiveness research! – 248					
17:00 - 18:00	ASCEPT AGM								
	Room: Boulevard Auditorium								
19:00 - 23:00	Meeting dinner								
	Boulevard Room, Brisbane Conve	ention & Exhibition Centre		Boulevard Room. Brisbane Convention & Exhibition Centre					



Ranked first in Australia by the Nature Index for life sciences (2017)

Home to more than 4,000 higher

degree research students

100+ research centres

. . . . . . . . .

#### The University of Queensland has been creating change for more than a century and has maintained an international reputation for research discovery, engagement and impact.

Encouraged by a stellar record of success and the prospect of helping solve the world's great challenges, UQ people refuse to accept the status quo and aim to deliver benefits to society and the environment worldwide.

#### Learn more at: research.uq.edu.au



Create change

Department of Pharmacology and Therapeutics, School of Biomedical Sciences

#### RESEARCH AND COLLABORATION OPPORTUNITIES Join Australia's leading University

Exciting research and collaborative opportunities with industry engagement in an innovative and inclusive environment for both early career and established researchers. Current projects include:

#### Lung Health Research Centre

A collaboration with the Royal Melbourne Hospital fostering translational research excellence, closely aligned with patient needs to improve their lung health.

#### The ARC Centre for Personalised Therapeutics Technologies (CPTT)

A major focus of the newly-established ARC Centre for Personalised Therapeutics Technologies, based at the University of Melbourne, is on new applications of mechanopharmacology and organ-on-a-chip technology. It will bring together the expertise needed to transform drug screening using microfluidic environments that are mechanically appropriate, with a focus on use of human cell culture. The Centre is a National collaboration with nodes at the University of Western Australia and Monash University.

#### Accelerating Australia

Accelerating Australia, funded by the MTPConnect Industry Growth Centre and 21 consortium members, and in affiliation with SPARK Global, will offer training in biomedical entrepreneurship in collaboration with the CPTT. This training will support new drug discovery projects as being sought under the joint venture between University of Melbourne, Monash University and BioCurate Pty Ltd.

#### Australian Venom Research Unit (AVRU)

An international networked group researching national and regional venomous injury problems and providing up to date information to health networks, industry, media and the community.

#### Visit our website:

http://biomedicalsciences.unimelb.edu.au/departments/pharmacology or contact Head of Department, Professor Daniel Hoyer E: d.hoyer@unimelb.edu.au



### Friday 8 December 2017

08:00-15:45	Registration desk open						
	Boulevard foyer, Brisbane Convention & Exhibition Centre						
08:30-09:30	APSA Medal Oration						
	Room: Boulevard Auditorium						
	Chair: Prof Andrew McLachlan						
	Colloids, carriers and collaborat	ions: A pathway to enhanced dru	ug delivery – <mark>300</mark>				
	Prof Chris Porter, Monash Institut	te of Pharmaceutical Sciences (M	IPS), Monash University				
09:30 - 10:25	Morning tea with exhibitors						
10:30 - 12:30	Symposium 9: Certara New Investigator Award	<b>Symposium 10:</b> The blood- brain barrier: A regulator of CNS drug access and disease progression	Symposium 11: The ethics of selling or recommending complementary medicines	Symposium 12: APSA Early Career Researchers			
	Sponsored by	Sponsored by	Sponsored by				
	CERTARA <sup>O</sup>	GENESEARCH e * F R E E Z E R					
	Room: Boulevard Auditorium	Room: Meeting room B3	Room: Meeting room B2	Room: Meeting room B1			
	Chair: Prof Carl Kirkpatrick	Chair: Dr Joe Nicolazzo	Chair: Dr Jasmina Fejzić	Chair: Prof Kevin Batty			
10:30 - 11:00	The use of oral anticoagulants in people with dementia – 301 Dr Jenni Ilomaki, Monash University	BBB permeability of molecularly-targeted anti- tumor agents: necessary for effective treatment of brain tumors – 305 Prof William Elmquist, University of Minnesota, USA	<b>Complementary medicines,</b> health professional responsibilities and trust – 309 Prof Eleanor Milligan, Griffith University	How to reliably measure customers' perceptions of service quality in community pharmacy – 313 Dr Stephen Carter, The University of Sydney			
11:00 - 11:30	Strategies for precision use of targeted anti-cancer medicines – 302 Dr Andrew Rowland, Flinders University	Clearance of beta-amyloid is facilitated by apolipoprotein E (apoE) and circulating high- density lipoproteins (HDL) in bioengineered human vessels - 306 Prof Cheryl Wellington, University of British Columbia, Canada	What are the potential harms of complementary medicines? – 310 Dr Geraldine Moses, Mater Hospital; The University of Queensland	The safety of transdermal fentanyl initiation in Australian clinical practice – 314 Dr Natasa Gisev, University of New South Wales			
11:30 - 12:00	Big data: Driving innovation for geriatric pharmacoepidemiology and pharmacovigilance research – 303 Dr Prasad Nishtala, University of Otago, New Zealand	HIV infection and Alzheimer's disease: The integral role of the blood-brain barrier – 307 Prof Michal Toborek, University of Miami, USA	Selling complementary medicines and the new Code of Ethics for Pharmacists – 311 Dr Adam La Caze, The University of Queensland	Personalized microneedle eye patches by 3D printing to treat peri-orbital wrinkles with a small peptide – 315 Dr Lifeng Kang, The University of Sydney			
12:00 – 12:30	Developing the next generation of analgesics – 304 Dr Jennifer Deuis, The University of Queensland	The cerebral vascular basement membrane: A target for Alzheimer's disease and stroke – 308 Prof Gregory Bix, University of Kentucky, USA	Regulating complementary medicines and pharmacy practice – 312 Assoc Prof Laetitia Hattingh, Griffith University	The provision of enhanced and extended services in Western Australian community pharmacies – 316 Dr Petra Czarniak, Curtin University			
12:30 – 13:25	Lunch with exhibitors and ASCEPT Workshop: MedicineInsight – Big c (please take lunch into room with Room: Meeting room B1	lata to support health research and		NPS MEDICINEWISE			

## ANNUAL SCIENTIFIC MEETING



Innovation in therapeutics: Fundamental research to clinical impact

27-30 November 2018 ADELAIDE CONVENTION CENTRE www.ascept.org

13:30 – 15:00	Oral presentations 13: Drug Discovery / Pharmaceutical Science Supported by MONASH University Institute of Pharmaceutical Sciences	Oral presentations 14: Clinical trainees	Oral presentations 15: Pharmacogenomics	Oral presentations 16: Education
	Room: Boulevard Auditorium	Room: Meeting room B3	Room: Meeting room B2	Room: Meeting room B1
	Chair: Dr Karen Gregory	Chair: Dr Paul Chin	<b>Chairs:</b> Assoc Prof Nuala Helsby and Dr Marina Junqueira Santiago	Chair: Assoc Prof Elizabeth Davis
13:30 – 13:45	Reversal of age related pseudocapillarization utilising vascular endothelial growth factor related, nitric oxide dependent drug treatments on <i>in vitro</i> liver sinusoidal endothelial cells – 317 Dr Nicholas Hunt, Anzac Research Institute, The University of Sydney	A randomised controlled trial of patient information leaflets as a medication counselling tool – 323 Dr Richard McNeill, Canterbury District Health Board, New Zealand	No significant effect of CYP3A, ABCB1, POR and NR1/2 polymorphisms on acute rejection and nephrotoxicity in the first 3 months post kidney transplantation in patients receiving tacrolimus – 329 Ms Rong Hu, The University of Adelaide	Best possible medication history gamification – development and pilot study – 335 Dr Paulina Stehlik, Bond University
13:45 – 14:00	Cell-specific and biased signalling of a peptide mimetic and small molecule at the relaxin receptor RXFP1 – 318 Dr Martina Kocan, Florey Institute of Neuroscience and Mental Health	<b>"Therapy induced" Takotsubo</b> <b>Cardiomyopathy: Does it</b> <b>matter? – 324</b> Dr Gao Jing Ong, Queen Elizabeth Hospital	HLA-B status leading to potential severe adverse drug reactions in Aboriginal Australians – 330 Prof Andrew Somogyi, University of Adelaide	Engaging students in learning outcomes and career relevance through a multi- dimensional, interactive map – MyCourseMap – 336 Assoc Prof Lisa Tee, Curtin University
14:00 - 14:15	Investigation of the insulin mimetic effect of <i>Teucrium</i> <i>polium in vitro</i> – <b>319</b> Dr Rima Caccetta, Curtin University	A physiological based pharmacokinetic model to guide dosing of ivacaftor in the presence of pharmacoenhancers – 325 Dr Angela Rowland, Flinders Medical Centre	Potential simple and multifactorial drug and gene interactions of tricyclic antidepressants in older Australians – 331 Mr Mohitosh Biswas, The University of Newcastle	"Visual thinking strategies" in early pharmacy undergraduate education can support the development of professional communication and cultural competencies – 337 Dr Trudi Aspden, University of Auckland, New Zealand
14:15 – 14:30	Measuring ligand-binding in endosomes: A signalling platform for pain transmission – 320 Dr Nicholas Veldhuis, Monash University	Evaluation of the role and impact of brain computed tomography scans in the assessment of clinically diagnosed overdose cases and an attempt to formulate a procedural framework – 326 Dr Emma Tay, St Vincent's Hospital	Signalling modification by Single Nucleotide Polymorphisms in the third intracellular loop of the mu- opioid receptor – 332 Dr Marina Junqueira Santiago, Macquarie University	Experiences developing a pharmacology online careers portal: Evaluating impact on student career awareness – 338 Dr Barbara Kemp-Harper, Monash University
14:30 – 14:45	Mutations in the NPxxY motif stabilise different conformational states of the $\alpha_{1B}$ - and $\beta_2$ -adrenoceptors - 321 Dr Lotten Ragnarsson, The University of Queensland	Real-time review of electronic prescribing of restricted antimicrobials - a pilot of a new antimicrobial stewardship initiative for Christchurch Hospital – 327 Dr Niall Hamilton, Canterbury District Health Board, New Zealand	ABCB1 pharmacogenetics in Papua New Guinea HIV/AIDS patients and association with efavirenz CNS/Psychiatric adverse effects – 333 Miss Helena Van Schalkwyk, University of Adelaide	Exploring the use of a novel computer-based interactive pharmacy simulation program in university and professional pharmacy practice education - 339 Dr Kenneth Lee, University of Tasmania
14:45 – 15:00	Drug delivery to the intestinal lymphatics enhances the immunosuppressant effects of mycophenolic acid in mice – 322 Mrs Ruby Panakkal Kochappan, Monash University	Thyroid immune-related adverse events following PD-1 inhibitors for cancer: Characteristics and associations – 328 Dr Frida Djukiadmodjo, Austin Health	Interleukin genetics and not COMT or OPRM1 may affect risk of persistent pain following total knee arthroplasty – 334 Dr Daniel Barratt, University of Adelaide	The journey of a prescription: An interprofessional education simulation of the patient and prescription flow through prescriber and dispenser – 340 Dr James Green, University of Otago, New Zealand
15:00 – 15:15	Comfort break			
15:15 – 15:45	Awards and meeting close Room: Boulevard Auditorium Chairs: Dr Joseph Nicolazzo and Pro	of Carl Kirkpatrick		

# Therapeutic Guidelines

### Thank you to our sponsors



### **Meeting secretariat**



PO Box 351 Hamilton Central Qld 4007 Australia Phone: +61 7 3848 2100 Email: apsa-ascept2017@expertevents.com.au